Back to News & Events

Join us at io360! February 7-10 in Brooklyn NY

The 9th annual Immuno-Oncology 360° Summit, taking place February 7-10, 2023 in Brooklyn, NY, offers an unparalleled opportunity to hear from stakeholders representing both the science and business communities who report on the latest data impacting IO.

Center for Biotechnology constituents receive a 15% Discount on registration with code “CFB15”

Learn more at www.IO360Summit.com

Related Stories

WP_Query Object
(
    [query] => Array
        (
            [post_type] => post
            [posts_per_page] => 3
            [post_status] => publish
            [orderby] => rand
        )

    [query_vars] => Array
        (
            [post_type] => post
            [posts_per_page] => 3
            [post_status] => publish
            [orderby] => rand
            [error] => 
            [m] => 
            [p] => 0
            [post_parent] => 
            [subpost] => 
            [subpost_id] => 
            [attachment] => 
            [attachment_id] => 0
            [name] => 
            [pagename] => 
            [page_id] => 0
            [second] => 
            [minute] => 
            [hour] => 
            [day] => 0
            [monthnum] => 0
            [year] => 0
            [w] => 0
            [category_name] => 
            [tag] => 
            [cat] => 
            [tag_id] => 
            [author] => 
            [author_name] => 
            [feed] => 
            [tb] => 
            [paged] => 0
            [meta_key] => 
            [meta_value] => 
            [preview] => 
            [s] => 
            [sentence] => 
            [title] => 
            [fields] => all
            [menu_order] => 
            [embed] => 
            [category__in] => Array
                (
                )

            [category__not_in] => Array
                (
                )

            [category__and] => Array
                (
                )

            [post__in] => Array
                (
                )

            [post__not_in] => Array
                (
                )

            [post_name__in] => Array
                (
                )

            [tag__in] => Array
                (
                )

            [tag__not_in] => Array
                (
                )

            [tag__and] => Array
                (
                )

            [tag_slug__in] => Array
                (
                )

            [tag_slug__and] => Array
                (
                )

            [post_parent__in] => Array
                (
                )

            [post_parent__not_in] => Array
                (
                )

            [author__in] => Array
                (
                )

            [author__not_in] => Array
                (
                )

            [search_columns] => Array
                (
                )

            [ignore_sticky_posts] => 
            [suppress_filters] => 
            [cache_results] => 1
            [update_post_term_cache] => 1
            [update_menu_item_cache] => 
            [lazy_load_term_meta] => 1
            [update_post_meta_cache] => 1
            [nopaging] => 
            [comments_per_page] => 50
            [no_found_rows] => 
            [order] => 
        )

    [tax_query] => WP_Tax_Query Object
        (
            [queries] => Array
                (
                )

            [relation] => AND
            [table_aliases:protected] => Array
                (
                )

            [queried_terms] => Array
                (
                )

            [primary_table] => wp_posts
            [primary_id_column] => ID
        )

    [meta_query] => WP_Meta_Query Object
        (
            [queries] => Array
                (
                )

            [relation] => 
            [meta_table] => 
            [meta_id_column] => 
            [primary_table] => 
            [primary_id_column] => 
            [table_aliases:protected] => Array
                (
                )

            [clauses:protected] => Array
                (
                )

            [has_or_relation:protected] => 
        )

    [date_query] => 
    [request] => SELECT SQL_CALC_FOUND_ROWS  wp_posts.ID
					 FROM wp_posts 
					 WHERE 1=1  AND wp_posts.post_type = 'post' AND ((wp_posts.post_status = 'publish'))
					 
					 ORDER BY RAND()
					 LIMIT 0, 3
    [posts] => Array
        (
            [0] => WP_Post Object
                (
                    [ID] => 5065
                    [post_author] => 4
                    [post_date] => 2026-09-01 14:03:32
                    [post_date_gmt] => 2026-09-01 18:03:32
                    [post_content] => 

Applications are now open for the 12th BioREACH Award Program from the Center for Biotechnology, which provides $50,000 in translational research funding for Stony Brook faculty and postdoctoral researchers to generate the evidence needed to advance promising innovations to the next stage of development.

BioREACH funds milestone-driven studies and welcomes biomedical innovations as well as platforms, tools, computational technologies, and other enabling technologies with the potential to contribute to solutions addressing unmet needs in health.

Application deadline: October 29, 2026, 5:00pm ET

For info sessions, eligibility and deadlines visit our REACH Website and FAQ.

The Center for Biotechnology (CfB) has helped advance some of Stony Brook University’s most impactful biomedical innovations, among them the yeast two-hybrid system, Xiaflex®, ReoPro®, Oracea®, and 3D virtual colonoscopy. The CfB has supported more than 475 faculty-led translational research projects and contributed to 306 license agreements generating $51 million in royalty returns to the University.

Questions? Reach out to our program contacts or sign up for office hours:

Dee Dao, PhD, Associate Director, dee.dao@stonybrook.edu
Office Hours: Monday–Friday, 2–3:30 PM | Sign up Here

Zelda Mendelowitz, PhD, Venture Associate, zelda.mendelowitz@stonybrook.edu
Office Hours: Tuesday, Wednesday, Friday, 8–11 AM | Sign up Here

[post_title] => BioREACH: Translational Research Funding Opportunity [post_excerpt] => [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => bioreach-translational-research-funding-opportunity [to_ping] => [pinged] => [post_modified] => 2026-09-04 11:55:36 [post_modified_gmt] => 2026-09-04 15:55:36 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=5065 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [1] => WP_Post Object ( [ID] => 5140 [post_author] => 4 [post_date] => 2026-10-20 11:58:48 [post_date_gmt] => 2026-10-20 15:58:48 [post_content] =>

Envisagenics announced that it has been awarded a Direct to Phase II SBIR grant from the National Cancer Institute (NCI). The award will provide more than $2 million over two years to support further development and commercialization of SpliceCore®, including SpliceDisco™, a new machine learning algorithm designed to connect cancer-specific therapeutic targets with the splicing mechanisms that drive disease. With this capability, Envisagenics can prioritize targets with strong biological rationale and therapeutic potential.

The project funded with this grant will support the development of SpliceDisco. By combining AI-driven prioritization with experimental validation, the project is designed to generate cancer-specific, partner-ready therapeutic target opportunities with defined disease relevance, patient prevalence, and modality fit across Envisagenics’ internal oncology pipeline and external collaboration programs.

Read more about the award, and Evisagenic's SpliceCore® technology here.

[post_title] => Envisagenics Awarded $2M+ Direct to Phase II NCI SBIR Grant [post_excerpt] => [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => envisagenics-awarded-2m-direct-to-phase-ii-nci-sbir-grant [to_ping] => [pinged] => [post_modified] => 2026-10-20 11:58:48 [post_modified_gmt] => 2026-10-20 15:58:48 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=5140 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [2] => WP_Post Object ( [ID] => 4348 [post_author] => 4 [post_date] => 2024-01-08 14:02:46 [post_date_gmt] => 2024-01-08 19:02:46 [post_content] =>

Join us for one or both of our upcoming intensive, SBIR/STTR proposal development workshops focusing on preparing to submit to the National Institutes of Health (NIH) and the National Science Foundation (NSF) SBIR/STTR programs.

January 24-25, 2024 - National Institutes of Health
1/24: 10:00am - 11:30am, 2:00pm-3:30pm; 1/25:10:00am - 11:30am

February 1, 2024 - National Science Foundation
9:00am - 2:30pm.

Learn from our experts important information about SBIR/STTR funding and how to craft a competitive SBIR/STTR proposal that meets the unique requirements of each agency. Our NIH session will span three short sessions over two days and include STTR/SBIR program overviews and detailed explanations of the major proposal components. The NSF session will include a detailed NSF program overview and review the key elements of an NSF proposal.

Individual workshop registration fee: $15.00. NIH/NSF package $25.00. Click here to register. https://cfbsbirtrain2024a.eventbrite.com

Workshop organized by the Center for Biotechnology at Stony Brook University and Columbia Technology Ventures, content delivered by BBC Entrepreneurial Training and Consulting.

[post_title] => Virtual SBIR/STTR Workshops: NIH & NSF [post_excerpt] => Join us for one or both of our upcoming intensive, SBIR/STTR proposal development workshops focusing on preparing to submit to the National Institutes of Health (NIH) and the National Science Foundation (NSF) SBIR/STTR programs. [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => virtual-sbir-sttr-workshops-nih-nsf [to_ping] => [pinged] => [post_modified] => 2024-08-22 11:36:51 [post_modified_gmt] => 2024-08-22 15:36:51 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=4348 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [3] => WP_Post Object ( [ID] => 1932 [post_author] => 4 [post_date] => 2015-12-30 21:39:54 [post_date_gmt] => 2015-12-30 21:39:54 [post_content] =>

DepYmed, a joint venture of Cold Spring Harbor Laboratory and New York City-based biotech Ohr Pharmaceutical led by Andreas Grill, has received $100,000 from Accelerate Long Island and the Long Island Emerging Technologies Fund. Andreas Grill has served as a BioEntrepreneur-in-Residence for the center for Biotechnology and DepYmed is developing a new drug called Trodusquemine that it hopes will one day treat HER2-positive breast cancer, an aggressive form of the disease. Read more about the company and the investment from Accelerate and LIETF here.

[post_title] => Depymed Received $100k from Accelerate Long Island & LIETF [post_excerpt] => DepYmed has received $100,000 from Accelerate Long Island and the Long Island Emerging Technologies Fund. [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => depymed-received-100k-from-accelerate-long-island-lietf [to_ping] => [pinged] => [post_modified] => 2016-03-29 20:28:36 [post_modified_gmt] => 2016-03-29 20:28:36 [post_content_filtered] => [post_parent] => 0 [guid] => http://centerforbiotechnology.org/new/?p=1932 [menu_order] => 193 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) ) [post_count] => 4 [current_post] => -1 [before_loop] => 1 [in_the_loop] => [post] => WP_Post Object ( [ID] => 5065 [post_author] => 4 [post_date] => 2026-09-01 14:03:32 [post_date_gmt] => 2026-09-01 18:03:32 [post_content] =>

Applications are now open for the 12th BioREACH Award Program from the Center for Biotechnology, which provides $50,000 in translational research funding for Stony Brook faculty and postdoctoral researchers to generate the evidence needed to advance promising innovations to the next stage of development.

BioREACH funds milestone-driven studies and welcomes biomedical innovations as well as platforms, tools, computational technologies, and other enabling technologies with the potential to contribute to solutions addressing unmet needs in health.

Application deadline: October 29, 2026, 5:00pm ET

For info sessions, eligibility and deadlines visit our REACH Website and FAQ.

The Center for Biotechnology (CfB) has helped advance some of Stony Brook University’s most impactful biomedical innovations, among them the yeast two-hybrid system, Xiaflex®, ReoPro®, Oracea®, and 3D virtual colonoscopy. The CfB has supported more than 475 faculty-led translational research projects and contributed to 306 license agreements generating $51 million in royalty returns to the University.

Questions? Reach out to our program contacts or sign up for office hours:

Dee Dao, PhD, Associate Director, dee.dao@stonybrook.edu
Office Hours: Monday–Friday, 2–3:30 PM | Sign up Here

Zelda Mendelowitz, PhD, Venture Associate, zelda.mendelowitz@stonybrook.edu
Office Hours: Tuesday, Wednesday, Friday, 8–11 AM | Sign up Here

[post_title] => BioREACH: Translational Research Funding Opportunity [post_excerpt] => [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => bioreach-translational-research-funding-opportunity [to_ping] => [pinged] => [post_modified] => 2026-09-04 11:55:36 [post_modified_gmt] => 2026-09-04 15:55:36 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=5065 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [comment_count] => 0 [current_comment] => -1 [found_posts] => 288 [max_num_pages] => 96 [max_num_comment_pages] => 0 [is_single] => [is_preview] => [is_page] => [is_archive] => [is_date] => [is_year] => [is_month] => [is_day] => [is_time] => [is_author] => [is_category] => [is_tag] => [is_tax] => [is_search] => [is_feed] => [is_comment_feed] => [is_trackback] => [is_home] => 1 [is_privacy_policy] => [is_404] => [is_embed] => [is_paged] => [is_admin] => [is_attachment] => [is_singular] => [is_robots] => [is_favicon] => [is_posts_page] => [is_post_type_archive] => [query_vars_hash:WP_Query:private] => 325c4f9f1aebaa5ec90666fa54175ba0 [query_vars_changed:WP_Query:private] => [thumbnails_cached] => [allow_query_attachment_by_filename:protected] => [stopwords:WP_Query:private] => [compat_fields:WP_Query:private] => Array ( [0] => query_vars_hash [1] => query_vars_changed ) [compat_methods:WP_Query:private] => Array ( [0] => init_query_flags [1] => parse_tax_query ) [query_cache_key:WP_Query:private] => )

BioREACH: Translational Research Funding Opportunity

More Information

Envisagenics Awarded $2M+ Direct to Phase II NCI SBIR Grant

More Information

Virtual SBIR/STTR Workshops: NIH & NSF

More Information

Depymed Received $100k from Accelerate Long Island & LIETF

More Information